Engineering the Next Generation of Therapeutics

Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of the next generation of immunotoxins called engineered toxin bodies (ETBs) which are a novel class of therapeutics with unique biology and a differentiated mechanism of action. ETBs are targeted, are designed to induce their own internalization, even against non-internalizing receptors, and destroy tumor cells that are resistant to other modalities. ETBs have been well-tolerated in the clinic to date and show predictable pharmacokinetic and pharmacodynamic effects.

About Us

A New Modality Against Validated Targets

At Molecular Templates, we are developing a pipeline of ETBs that we believe will provide meaningful benefit to patients.  ETBs targeting some of the most important receptors in cancer are currently in clinical trials. Our lead compound, MT-3724, has shown monotherapy activity in patients who have progressed on all available therapies.

View Our Pipeline

Our Clinical Candidates

MT-3724: 1st-Gen ETB Targeting CD20 for Lymphomas

MT-3724 targets CD20, a non-internalizing B-cell lymphoma marker, and is currently in multiple Phase 2 clinical studies after demonstrating no life-threatening toxicities and strong signals of monotherapy activity in a Phase 1 study.

View Candidate

MT-5111: 2nd-Gen ETB Targeting HER2

MT-5111 targets HER2 for multiple solid tumors including breast and gastric cancer.

View Candidate

TAK-169: 2nd-Gen ETB Targeting CD38

TAK-169 targets CD38 for multiple myeloma. TAK-169 is being co-developed with Takeda Pharmaceutical Company Limited.

View Candidate
mail icon

Email Alerts

Stay informed and receive company updates straight to your inbox.

Learn More